Opinion statement
Carcinoma of the vulva is an uncommon gynecologic malignancy primarily affecting postmenopausal women. The lesion is most commonly associated with HPV DNA, although, for many, a defined preinvasive to invasive connection is not readily apparent. Most patients experience symptoms of pruritus, irritation, and even pain for weeks or months before the diagnostic biopsy is performed. Patient embarrassment and unfamiliarity and reluctance on the part of the physician to fully evaluate these symptoms add to the delay. Vulvar carcinoma is staged surgically following resection. A concerted effort to conserve as much normal tissue as possible has been the focus of recent investigation. Separate incision resection of the vulvar mass and groin has improved wound healing and quality of life for many patients. The effect these conservative procedures have on long-term survival is currently being evaluated. Increased use of radiation therapy or chemoradiation has allowed organ preservation in many otherwise exenterative cases. In some instances, this neoadjuvant therapy has provided an opportunity to surgically clear otherwise unresectable lesions. Current radiotherapy techniques might also be as effective as groin dissection in certain low-risk patients. Adjuvant radiation and chemoradiation improve local control and reduce groin recurrence risk. In addition, patients with histologically positive groins enjoy longer survival when the pelvis is also treated. Selected use of multimodality therapy will likely extend the lives of women with vulvar cancer.
Similar content being viewed by others
References and Recommended Reading
Practice guidelines: vulvar cancer. Society of Gynecologic Oncologists Clinical Practice Guidelines. Oncology (Huntingt) 1998, 12:275–282. This article outlines the clinical practice guidelines set forth by the SGO. It is comprehensive and references the classic articles defining vulvar cancer management
Basta A, Adamek K, Pitynski K: Intraepithelial neoplasia and early stage vulvar cancer. Epidemiological, clinical and virological observations. Eur J Gynaecol Oncol 1999, 20:111–114.
Creasman WT, Phillips JL, Menck HR: The National Cancer Data Base report on early stage invasive vulvar carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1997, 80:505–513.
Wilkinson E: Premalignant and malignant tumors of the vulva. In Blaustein’s Pathology of the Female Genital Tract. Edited by Kurman R. New York: Springer-Verlag; 1995.
Hildesheim A, Han CL, Brinton LA, et al.: Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: results from a seroepidemiological case-control study [see comments]. Obstet Gynecol 1997, 90:748–754.
Madeleine MM, Daling JR, Carter JJ, et al.: Cofactors with human papillomavirus in a population-based study of vulvar cancer [published erratum appears in J Natl Cancer Inst 1997 Dec 17;89(24):1896]. J Natl Cancer Inst 1997, 89:1516–1523.
Flowers LC, Wistuba II, Scurry J, et al.: Genetic changes during the multistage pathogenesis of human papillomavirus positive and negative vulvar carcinomas. J Soc Gynecol Investig 1999, 6:213–221.
American Joint Committee on Cancer: AJCC Cancer Staging Manual. Philadelphia, PA: Lippincott-Raven Publishers; 1997.
Shepherd JH: Cervical and vulva cancer: changes in FIGO definitions of staging [see comments]. Br J Obstet Gynaecol 1996, 103:405–406.
Chiasson MA, Ellerbrock TV, Bush TJ, et al.: Increased prevalence of vulvovaginal condyloma and vulvar intraepithelial neoplasia in women infected with the human immunodeficiency virus. Obstet Gynecol 1997, 89:690–694.
Modesitt SC, Waters AB, Walton L, et al.: Vulvar intraepithelial neoplasia III: occult cancer and the impact of margin status on recurrence [see comments]. Obstet Gynecol 1998, 92:962–966.
Rettenmaier MA: Vulvar intraepithelial neoplasia III: occult cancer and the impact of margin status on recurrence [letter; comment]. Obstet Gynecol 1999, 93:633–634.
Husseinzadeh N, Recinto C: Frequency of invasive cancer in surgically excised vulvar lesions with intraepithelial neoplasia (VIN 3). Gynecol Oncol 1999, 73:119–120. This important paper demonstrates the common finding of unexpected invasive cancer among patients undergoing excision of high-grade dysplasia
Rettenmaier MA, Berman ML, DiSaia PJ: Skinning vulvectomy for the treatment of multifocal vulvar intraepithelial neoplasia. Obstet Gynecol 1987, 69:247–250.
Reid R, Greenberg MD, Lorincz AT, et al.: Superficial laser vulvectomy. IV. Extended laser vaporization and adjunctive 5-fluorouracil therapy of human papillomavirus-associated vulvar disease. Obstet Gynecol 1990, 76:439–448.
Baggish MS, Dorsey JH: CO2 laser for the treatment of vulvar carcinoma in situ. Obstet Gynecol 1981, 57:371–375.
Reid R: Superficial laser vulvectomy. III. A new surgical technique for appendage-conserving ablation of refractory condylomas and vulvar intraepithelial neoplasia. Am J Obstet Gynecol 1985, 152:504–509.
Miller B, Katasanis W: Treatment of vulvar intraepithelial neoplasia with ultrasonic surgical aspiration. Proc Am Soc Clin Oncol 1999, 18:380a.
Reid R, Greenberg MD, Pizzuti DJ, et al.: Superficial laser vulvectomy. V. Surgical debulking is enhanced by adjuvant systemic interferon. Am J Obstet Gynecol 1992, 166:815–820.
Krebs HB: Prophylactic topical 5-fluorouracil following treatment of human papillomavirus-associated lesions of the vulva and vagina. Obstet Gynecol 1986, 68:837–841.
Lifshitz S, Roberts JA: Treatment of carcinoma in situ of the vulva with topical 5-fluorouracil. Obstet Gynecol 1980, 56:242–244.
Kelley JLD, Burke TW, Tornos C, et al.: Minimally invasive vulvar carcinoma: an indication for conservative surgical therapy. Gynecol Oncol 1992, 44:240–244.
Homesley HD, Bundy BN, Sedlis A, et al.: Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study). Am J Obstet Gynecol 1991, 164:997–1003; discussion 1003-1004.
Burke TW, Levenback C, Coleman RL, et al.: Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy. Gynecol Oncol 1995, 57:215–220.
Hacker NF: Current management of early vulvar cancer. Ann Acad Med Singapore 1998, 27:688–692.
Heaps JM, Fu YS, Montz FJ, et al.: Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol 1990, 38:309–314.
Hacker NF, Van der Velden J: Conservative management of early vulvar cancer. Cancer 1993, 71:1673–1637.
Levenback C, Morris M, Burke TW, et al.: Groin dissection practices among gynecologic oncologists treating early vulvar cancer [see comments]. Gynecol Oncol 1996, 62:73–77.
Stehman FB, Bundy BN, Dvoretsky PM, Creasman WT: Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. Obstet Gynecol 1992, 79:490–497.
Stehman FB, Bundy BN, Thomas G, et al.: Groin dissection versus groin radiation in carcinoma of the vulva: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 1992, 24:389–396.
Petereit DG, Mehta MP, Buchler DA, Kinsella TJ: Inguinofemoral radiation of N0,N1 vulvar cancer may be equivalent to lymphadenectomy if proper radiation technique is used [see comments]. Int J Radiat Oncol Biol Phys 1993, 27:963–967.
Berman ML, Soper JT, Creasman WT, et al.: Conservative surgical management of superficially invasive stage I vulvar carcinoma. Gynecol Oncol 1989, 35:352–357.
Levenback C, Burke TW, Morris M, et al.: Potential applications of intraoperative lymphatic mapping in vulvar cancer. Gynecol Oncol 1995, 59:216–220.
Outwater E, Kressel HY: Evaluation of gynecologic malignancy by magnetic resonance imaging. Radiol Clin North Am 1992, 30:789–806.
De Cicco C, Sideri M, Bartolomei M, et al.: Sentinel node biopsy in early vulvar cancer. Br J Cancer 2000, 82:295–299. Dr. De Cicco and colleagues present provocative data on the emerging role of intraoperative lymphatic mapping using lymphoscintigraphy. In the study, no patients had metastatic disease outside the designated sentinel node. If validated, this technique could replace lymphadenectomy offering a less morbid alternative to evaluation of the groin
Cunningham MJ, Goyer RP, Gibbons SK, et al.: Primary radiation, cisplatin, and 5-fluorouracil for advanced squamous carcinoma of the vulva. Gynecol Oncol 1997, 66:258–261.
Eifel PJ, Morris M, Burke TW, et al.: Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva. Gynecol Oncol 1995, 59:51–56.
Leiserowitz GS, Russell AH, Kinney WK, et al.: Prophylactic chemoradiation of inguinofemoral lymph nodes in patients with locally extensive vulvar cancer. Gynecol Oncol 1997, 66:509–514.
Moore DH, Thomas GM, Montana GS, et al.: Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys 1998, 42:79–85.
Hopkins MP, Morley GW: Pelvic exenteration for the treatment of vulvar cancer. Cancer 1992, 70:2835–2838.
Miller B, Morris M, Levenback C, et al.: Pelvic exenteration for primary and recurrent vulvar cancer. Gynecol Oncol 1995, 58:202–205.
Homesley HD, Bundy BN, Sedlis A, Adcock L: Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet Gynecol 1986, 68:733–740.
Perez CA, Grigsby PW, Chao C, et al.: Irradiation in carcinoma of the vulva: factors affecting outcome. Int J Radiat Oncol Biol Phys 1998, 42:335–344.
Perez CA, Grigsby PW, Galakatos A, et al.: Radiation therapy in management of carcinoma of the vulva with emphasis on conservation therapy. Cancer 1993, 71:3707–3716.
Paley PJ, Johnson PR, Adcock LL, et al.: The effect of sartorius transposition on wound morbidity following inguinal-femoral lymphadenectomy. Gynecol Oncol 1997, 64:237–241.
Chafe W, Fowler WC, Walton LA, Currie JL: Radical vulvectomy with use of tensor fascia lata myocutaneous flap. Am J Obstet Gynecol 1983, 145:207–213.
Faul CM, Mirmow D, Huang Q, et al.: Adjuvant radiation for vulvar carcinoma: improved local control. Int J Radiat Oncol Biol Phys 1997, 38:381–389.
Homesley HD: Management of vulvar cancer. Cancer 1995, 76:2159–2170.
Paladini D, Cross P, Lopes A, Monaghan JM: Prognostic significance of lymph node variables in squamous cell carcinoma of the vulva [see comments]. Cancer 1994, 74:2491–2496.
van der Velden J, van Lindert AC, Lammes FB, et al.: Extracapsular growth of lymph node metastases in squamous cell carcinoma of the vulva. The impact on recurrence and survival. Cancer 1995, 75:2885–2890.
Bouma J, Dankert J: Recurrent acute leg cellulitis in patients after radical vulvectomy. Gynecol Oncol 1988, 29:50–57.
Hoffman MS, Mark JE, Cavanagh D: A management scheme for postoperative groin lymphocysts. Gynecol Oncol 1995, 56:262–265.
Tewari K, Cappuccini F, Syed AM, et al.: Interstitial brachytherapy in the treatment of advanced and recurrent vulvar cancer. Am J Obstet Gynecol 1999, 181:91–98.
Trimble EL, Lewis JL Jr, Williams LL, et al.: Management of vulvar melanoma. Gynecol Oncol 1992, 45:254–258.
Trimble EL: Melanomas of the vulva and vagina. Oncology (Huntingt) 1996, 10:1017–1023; discussion 1024.
Singhal RM, Narayana A: Malignant melanoma of the vulva: response to radiation. Br J Radiol 1991, 64:846–847.
Copeland LJ, Sneige N, Gershenson DM, et al.: Bartholin gland carcinoma. Obstet Gynecol 1986, 67:794–801.
Fanning J, Lambert HC, Hale TM, et al.: Paget’s disease of the vulva: prevalence of associated vulvar adenocarcinoma, invasive Paget’s disease, and recurrence after surgical excision. Am J Obstet Gynecol 1999, 180:24–27.
DiSaia PJ, Dorion GE, Cappuccini F, Carpenter PM: A report of two cases of recurrent Paget’s disease of the vulva in a split-thickness graft and its possible pathogenesis-labeled“retrodissemination”. Gynecol Oncol 1995, 57:109–112.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Coleman, R.L., Santoso, J.T. Vulvar carcinoma. Curr. Treat. Options in Oncol. 1, 177–190 (2000). https://doi.org/10.1007/s11864-000-0063-4
Issue Date:
DOI: https://doi.org/10.1007/s11864-000-0063-4